Unusually, the UK parliament ended up getting involved, perhaps underlining the importance of AZ to the country’s life sciences sector ... was looking to acquire Gilead, known for its high ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

In the latest market close, Gilead Sciences (GILD) reached $98.38, with a +1.21% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best wide moat stocks to invest in. Russell Investments continues to monitor and ...

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...